BioSpace News Archive

Upon completion of the Exchange, the Company will no longer have any warrants outstanding from the 2017 Financings.

Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will present at the Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 8:00 a.m. ET in New York.

Capital Pro-Égaux Inc. announces that its wholly owned subsidiary, Technique d’usinage Sinlab Inc., has entered into a Litigation Funding Agreement for the funding of expenses related to the professional negligence action for damages commenced in 2013 in Florida against Sinlab’s counsel who represented Sinlab in litigation in Virginia against certain entities who violated Sinlab’s pioneering digital dentistry patent portfolio.

Before embarking on their trips, Canadian travellers should be mindful that, in most cases, their health coverage does not follow them abroad.

If You’ve had a Heart Attack or Stroke, Your Risk of Having Another Cardiovascular Event is Nearly One in Three

Agreement to acquire Osiris, a fast growing company delivering regenerative medicine products, including skin, bone graft and articular cartilage substitutes, for $19.00 per share in cash, representing a total equity value of approximately $660 million.

OncoTracker has years of experience accurately measuring soluble BCMA in the blood of thousands of multiple myeloma patients.

Truepill announced that it is launching a new B2B pharmacy fulfillment service which powers direct-to-consumer healthcare brands like Hims and Nurx.

Osage University Partners, a Philadelphia area-based venture capital firm, announced the closing of Osage University Partners III, L.P. at $273 million, exceeding its target of $250 million.

The U.S. Food and Drug Administration published four draft guidances and one final guidance regarding cancer trial eligibility criteria.